Okechukwu Samuel Ogah, M.Sc.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nigeria | 45 | 2024 | 779 | 2.840 |
Why?
|
Hypertension | 38 | 2024 | 8615 | 2.040 |
Why?
|
Heart Failure | 25 | 2024 | 11858 | 1.330 |
Why?
|
Registries | 16 | 2024 | 8379 | 1.260 |
Why?
|
Stroke | 26 | 2024 | 9742 | 0.940 |
Why?
|
Rheumatic Heart Disease | 6 | 2024 | 164 | 0.920 |
Why?
|
Noonan Syndrome | 1 | 2024 | 122 | 0.880 |
Why?
|
Starvation | 1 | 2022 | 141 | 0.800 |
Why?
|
Perindopril | 4 | 2022 | 13 | 0.740 |
Why?
|
Cardiovascular Diseases | 9 | 2023 | 15649 | 0.660 |
Why?
|
Echocardiography | 16 | 2024 | 5044 | 0.660 |
Why?
|
Amlodipine | 5 | 2024 | 84 | 0.640 |
Why?
|
Urban Population | 4 | 2014 | 2045 | 0.620 |
Why?
|
Africa South of the Sahara | 15 | 2024 | 751 | 0.600 |
Why?
|
Ghana | 13 | 2024 | 319 | 0.560 |
Why?
|
Atrial Fibrillation | 8 | 2024 | 5168 | 0.550 |
Why?
|
Malnutrition | 1 | 2022 | 631 | 0.520 |
Why?
|
Africa | 12 | 2024 | 726 | 0.520 |
Why?
|
Cardiomyopathy, Hypertrophic | 2 | 2024 | 1335 | 0.500 |
Why?
|
Hypertrophy, Left Ventricular | 10 | 2019 | 856 | 0.500 |
Why?
|
Pulmonary Heart Disease | 1 | 2014 | 34 | 0.480 |
Why?
|
Antihypertensive Agents | 7 | 2024 | 2027 | 0.470 |
Why?
|
Hydrochlorothiazide | 4 | 2022 | 95 | 0.410 |
Why?
|
Vitamin K | 4 | 2024 | 314 | 0.400 |
Why?
|
Life Style | 4 | 2024 | 3929 | 0.380 |
Why?
|
Patient Readmission | 4 | 2018 | 3312 | 0.370 |
Why?
|
Blood Pressure | 13 | 2024 | 8541 | 0.350 |
Why?
|
Middle Aged | 66 | 2024 | 223491 | 0.340 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2022 | 2537 | 0.340 |
Why?
|
Cardiomyopathies | 4 | 2024 | 2056 | 0.340 |
Why?
|
Risk Factors | 33 | 2024 | 74962 | 0.340 |
Why?
|
Research Design | 3 | 2023 | 6210 | 0.330 |
Why?
|
Adult | 55 | 2024 | 223640 | 0.320 |
Why?
|
Electrocardiography | 6 | 2024 | 6409 | 0.310 |
Why?
|
Diabetes Mellitus | 4 | 2022 | 5891 | 0.310 |
Why?
|
Prevalence | 14 | 2024 | 15872 | 0.310 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2014 | 843 | 0.300 |
Why?
|
Humans | 104 | 2024 | 768393 | 0.300 |
Why?
|
Male | 70 | 2024 | 364902 | 0.290 |
Why?
|
Cost of Illness | 2 | 2014 | 1959 | 0.290 |
Why?
|
Female | 69 | 2024 | 397089 | 0.290 |
Why?
|
Cerebral Hemorrhage | 5 | 2023 | 2653 | 0.280 |
Why?
|
Heart Diseases | 3 | 2011 | 2819 | 0.270 |
Why?
|
Outpatients | 1 | 2014 | 1604 | 0.270 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 4 | 2022 | 252 | 0.260 |
Why?
|
Developing Countries | 6 | 2024 | 2903 | 0.260 |
Why?
|
Length of Stay | 3 | 2015 | 6519 | 0.260 |
Why?
|
Acute Disease | 9 | 2018 | 7242 | 0.250 |
Why?
|
Aged | 41 | 2024 | 171562 | 0.250 |
Why?
|
Prospective Studies | 20 | 2024 | 54920 | 0.250 |
Why?
|
Indapamide | 1 | 2024 | 2 | 0.240 |
Why?
|
Hypertension, Pulmonary | 4 | 2017 | 1597 | 0.240 |
Why?
|
Pericarditis, Tuberculous | 2 | 2014 | 8 | 0.230 |
Why?
|
Case-Control Studies | 20 | 2024 | 22296 | 0.230 |
Why?
|
Peripartum Period | 2 | 2021 | 138 | 0.210 |
Why?
|
Coronary Artery Disease | 3 | 2023 | 6567 | 0.210 |
Why?
|
Ventricular Function, Left | 7 | 2023 | 3941 | 0.210 |
Why?
|
Inpatients | 1 | 2014 | 2570 | 0.210 |
Why?
|
Prednisolone | 2 | 2014 | 327 | 0.200 |
Why?
|
Mycobacterium | 2 | 2014 | 252 | 0.200 |
Why?
|
Pneumonia, Aspiration | 1 | 2023 | 145 | 0.200 |
Why?
|
Hospitalization | 9 | 2024 | 10844 | 0.190 |
Why?
|
Drug Combinations | 6 | 2024 | 2079 | 0.190 |
Why?
|
Prognosis | 16 | 2022 | 30022 | 0.190 |
Why?
|
Myocardial Ischemia | 4 | 2021 | 2139 | 0.190 |
Why?
|
Sex Distribution | 2 | 2024 | 2281 | 0.190 |
Why?
|
Urban Health | 2 | 2014 | 535 | 0.180 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 26375 | 0.180 |
Why?
|
Arrhythmias, Cardiac | 3 | 2021 | 2258 | 0.180 |
Why?
|
Gross Domestic Product | 1 | 2021 | 77 | 0.180 |
Why?
|
Cause of Death | 4 | 2024 | 3728 | 0.180 |
Why?
|
Resistin | 1 | 2021 | 172 | 0.180 |
Why?
|
Prehypertension | 1 | 2021 | 63 | 0.180 |
Why?
|
Ventricular Dysfunction, Left | 5 | 2024 | 2144 | 0.180 |
Why?
|
Heart Valve Diseases | 3 | 2018 | 1030 | 0.170 |
Why?
|
Economic Recession | 1 | 2021 | 79 | 0.170 |
Why?
|
Socioeconomic Factors | 4 | 2021 | 7861 | 0.170 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2021 | 136 | 0.170 |
Why?
|
Body Fat Distribution | 1 | 2021 | 246 | 0.170 |
Why?
|
Ventricular Remodeling | 3 | 2020 | 1281 | 0.170 |
Why?
|
Chloroquine | 1 | 2021 | 275 | 0.170 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2021 | 125 | 0.160 |
Why?
|
Smoking | 2 | 2016 | 9111 | 0.160 |
Why?
|
China | 2 | 2022 | 2395 | 0.160 |
Why?
|
Acute Coronary Syndrome | 2 | 2021 | 2192 | 0.150 |
Why?
|
Meta-Analysis as Topic | 1 | 2023 | 1364 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2024 | 1476 | 0.150 |
Why?
|
Sex Factors | 4 | 2024 | 10654 | 0.150 |
Why?
|
Puerperal Disorders | 1 | 2020 | 303 | 0.150 |
Why?
|
Endocarditis | 2 | 2024 | 352 | 0.140 |
Why?
|
Drug Therapy, Combination | 6 | 2024 | 6318 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 4047 | 0.140 |
Why?
|
Disclosure | 1 | 2023 | 754 | 0.140 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 426 | 0.140 |
Why?
|
Potassium | 1 | 2021 | 1318 | 0.140 |
Why?
|
Prediabetic State | 1 | 2022 | 548 | 0.130 |
Why?
|
Brain Ischemia | 2 | 2023 | 3008 | 0.130 |
Why?
|
Embolism | 1 | 2020 | 401 | 0.130 |
Why?
|
Pericardiocentesis | 2 | 2014 | 78 | 0.130 |
Why?
|
Sodium | 1 | 2021 | 1594 | 0.130 |
Why?
|
Quality Assurance, Health Care | 1 | 2006 | 2181 | 0.130 |
Why?
|
Heart Rate | 2 | 2017 | 4218 | 0.130 |
Why?
|
Adiponectin | 1 | 2021 | 1117 | 0.120 |
Why?
|
Heart Ventricles | 3 | 2017 | 3838 | 0.120 |
Why?
|
Patient Discharge | 3 | 2022 | 3476 | 0.120 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39407 | 0.120 |
Why?
|
Renal Insufficiency | 2 | 2014 | 809 | 0.120 |
Why?
|
Health Resources | 1 | 2021 | 950 | 0.120 |
Why?
|
Antimalarials | 1 | 2021 | 908 | 0.110 |
Why?
|
Anticoagulants | 4 | 2024 | 4843 | 0.110 |
Why?
|
Transportation of Patients | 1 | 2014 | 176 | 0.110 |
Why?
|
Young Adult | 11 | 2024 | 60049 | 0.110 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2014 | 275 | 0.110 |
Why?
|
Myocarditis | 1 | 2021 | 803 | 0.110 |
Why?
|
Comorbidity | 2 | 2024 | 10588 | 0.100 |
Why?
|
Tobacco, Smokeless | 1 | 2013 | 133 | 0.100 |
Why?
|
Heart Conduction System | 1 | 2017 | 1009 | 0.100 |
Why?
|
Stroke Volume | 6 | 2023 | 5619 | 0.100 |
Why?
|
Age Distribution | 2 | 2014 | 2877 | 0.100 |
Why?
|
Health Surveys | 2 | 2020 | 4056 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1943 | 0.100 |
Why?
|
Chronic Disease | 2 | 2024 | 9379 | 0.100 |
Why?
|
Rural Health | 1 | 2013 | 300 | 0.100 |
Why?
|
Health Personnel | 2 | 2023 | 3380 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2021 | 2006 | 0.090 |
Why?
|
International Normalized Ratio | 2 | 2024 | 382 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1881 | 0.090 |
Why?
|
Pericardial Effusion | 1 | 2012 | 246 | 0.090 |
Why?
|
Multicenter Studies as Topic | 3 | 2024 | 1727 | 0.090 |
Why?
|
Bacterial Vaccines | 1 | 2012 | 400 | 0.090 |
Why?
|
Transients and Migrants | 1 | 2013 | 170 | 0.090 |
Why?
|
Risk Assessment | 7 | 2023 | 24318 | 0.090 |
Why?
|
Age Factors | 6 | 2021 | 18471 | 0.090 |
Why?
|
Adolescent | 11 | 2023 | 89184 | 0.090 |
Why?
|
Coronary Disease | 1 | 2024 | 5924 | 0.090 |
Why?
|
Syphilis, Cardiovascular | 1 | 2009 | 2 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2021 | 4357 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1118 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2661 | 0.080 |
Why?
|
MEDLINE | 1 | 2009 | 119 | 0.080 |
Why?
|
Africa, Western | 2 | 2021 | 160 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1367 | 0.080 |
Why?
|
Disease | 1 | 2014 | 673 | 0.080 |
Why?
|
Malawi | 1 | 2009 | 309 | 0.080 |
Why?
|
Survival Analysis | 3 | 2018 | 10117 | 0.080 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15939 | 0.070 |
Why?
|
MicroRNAs | 1 | 2024 | 3804 | 0.070 |
Why?
|
Anemia | 1 | 2017 | 1519 | 0.070 |
Why?
|
Hospitals, University | 1 | 2009 | 569 | 0.070 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2024 | 518 | 0.070 |
Why?
|
Immunotherapy | 2 | 2014 | 4738 | 0.070 |
Why?
|
Single-Blind Method | 3 | 2019 | 1585 | 0.070 |
Why?
|
Survival Rate | 3 | 2017 | 12870 | 0.070 |
Why?
|
Genomics | 3 | 2024 | 5916 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5375 | 0.070 |
Why?
|
Ultrasonography, Doppler | 1 | 2008 | 463 | 0.070 |
Why?
|
Anemia, Sickle Cell | 1 | 2014 | 1065 | 0.060 |
Why?
|
Epidemiologic Studies | 1 | 2009 | 678 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20224 | 0.060 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15455 | 0.060 |
Why?
|
Logistic Models | 3 | 2019 | 13323 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14737 | 0.060 |
Why?
|
Glucocorticoids | 1 | 2014 | 2168 | 0.060 |
Why?
|
Asia | 2 | 2016 | 627 | 0.060 |
Why?
|
Heart Atria | 2 | 2008 | 1360 | 0.060 |
Why?
|
Cohort Studies | 3 | 2022 | 41795 | 0.060 |
Why?
|
Rheumatic Fever | 1 | 2024 | 73 | 0.060 |
Why?
|
Time Factors | 5 | 2021 | 40272 | 0.060 |
Why?
|
Incidence | 3 | 2021 | 21544 | 0.050 |
Why?
|
Hospital Mortality | 2 | 2015 | 5367 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2024 | 81801 | 0.050 |
Why?
|
Primary Prevention | 1 | 2011 | 1187 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2021 | 3118 | 0.050 |
Why?
|
Arginine | 1 | 2007 | 923 | 0.050 |
Why?
|
Residence Characteristics | 1 | 2013 | 2122 | 0.050 |
Why?
|
Thiazides | 1 | 2022 | 19 | 0.050 |
Why?
|
Rural Population | 1 | 2013 | 2318 | 0.050 |
Why?
|
Ventricular Function, Right | 2 | 2017 | 628 | 0.050 |
Why?
|
Infant | 2 | 2022 | 36510 | 0.050 |
Why?
|
Systole | 2 | 2019 | 937 | 0.050 |
Why?
|
Health Expenditures | 1 | 2014 | 2395 | 0.050 |
Why?
|
Odds Ratio | 3 | 2021 | 9682 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2017 | 4528 | 0.050 |
Why?
|
Infarction | 1 | 2023 | 247 | 0.050 |
Why?
|
South Africa | 2 | 2022 | 1871 | 0.050 |
Why?
|
Health Care Costs | 1 | 2014 | 3267 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10863 | 0.050 |
Why?
|
Potassium, Dietary | 1 | 2021 | 103 | 0.050 |
Why?
|
Treatment Outcome | 7 | 2022 | 65379 | 0.050 |
Why?
|
Diastole | 3 | 2008 | 784 | 0.040 |
Why?
|
Hand Strength | 1 | 2023 | 466 | 0.040 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 12778 | 0.040 |
Why?
|
Disease Progression | 2 | 2014 | 13646 | 0.040 |
Why?
|
Evidence-Based Medicine | 3 | 2018 | 3707 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6541 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 18048 | 0.040 |
Why?
|
Observer Variation | 1 | 2006 | 2623 | 0.040 |
Why?
|
Qualitative Research | 2 | 2023 | 3131 | 0.040 |
Why?
|
Heart Defects, Congenital | 1 | 2016 | 4713 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 692 | 0.040 |
Why?
|
Hemorrhage | 2 | 2022 | 3461 | 0.040 |
Why?
|
Morbidity | 1 | 2024 | 1758 | 0.040 |
Why?
|
Fruit | 1 | 2024 | 1164 | 0.040 |
Why?
|
Vegetables | 1 | 2024 | 1198 | 0.040 |
Why?
|
Feeding Behavior | 2 | 2024 | 3203 | 0.040 |
Why?
|
Nitric Oxide | 1 | 2007 | 2144 | 0.040 |
Why?
|
Alcohol Drinking | 2 | 2024 | 4049 | 0.040 |
Why?
|
Clergy | 1 | 2018 | 79 | 0.040 |
Why?
|
Angina, Unstable | 1 | 2021 | 893 | 0.040 |
Why?
|
Sodium, Dietary | 1 | 2021 | 426 | 0.040 |
Why?
|
Cerebral Infarction | 1 | 2022 | 975 | 0.040 |
Why?
|
Awareness | 1 | 2021 | 653 | 0.030 |
Why?
|
Child | 2 | 2022 | 80891 | 0.030 |
Why?
|
Obesity | 2 | 2021 | 13084 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3722 | 0.030 |
Why?
|
Aftercare | 1 | 2022 | 921 | 0.030 |
Why?
|
Diet | 2 | 2024 | 8090 | 0.030 |
Why?
|
Middle East | 1 | 2016 | 233 | 0.030 |
Why?
|
Pregnancy | 3 | 2024 | 30200 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1517 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2018 | 59686 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2024 | 12558 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10377 | 0.030 |
Why?
|
Developed Countries | 1 | 2018 | 452 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2016 | 520 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2016 | 305 | 0.030 |
Why?
|
Apolipoproteins B | 1 | 2016 | 386 | 0.030 |
Why?
|
Pericarditis, Constrictive | 1 | 2014 | 46 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2009 | 12241 | 0.030 |
Why?
|
Primary Health Care | 1 | 2011 | 4748 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2024 | 2240 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2021 | 873 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2022 | 12456 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1493 | 0.030 |
Why?
|
Cardiac Tamponade | 1 | 2014 | 175 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8753 | 0.030 |
Why?
|
Obesity, Abdominal | 1 | 2016 | 375 | 0.030 |
Why?
|
England | 1 | 2014 | 532 | 0.030 |
Why?
|
Echocardiography, Doppler | 2 | 2008 | 899 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1265 | 0.030 |
Why?
|
Focus Groups | 1 | 2018 | 1453 | 0.030 |
Why?
|
Myocardial Contraction | 1 | 2017 | 1527 | 0.020 |
Why?
|
Health Education | 1 | 2018 | 1057 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2019 | 1838 | 0.020 |
Why?
|
Family | 1 | 2023 | 3208 | 0.020 |
Why?
|
Organ Size | 2 | 2008 | 2268 | 0.020 |
Why?
|
Penicillins | 1 | 2014 | 406 | 0.020 |
Why?
|
Genetics, Medical | 1 | 2014 | 334 | 0.020 |
Why?
|
Health | 1 | 2014 | 399 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2014 | 794 | 0.020 |
Why?
|
Pilot Projects | 2 | 2014 | 8731 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7211 | 0.020 |
Why?
|
Ultrasonography | 3 | 2009 | 6001 | 0.020 |
Why?
|
Action Potentials | 1 | 2017 | 1838 | 0.020 |
Why?
|
Heart | 1 | 2023 | 4449 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1438 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3587 | 0.020 |
Why?
|
Antibiotic Prophylaxis | 1 | 2014 | 640 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2016 | 1322 | 0.020 |
Why?
|
Europe | 1 | 2016 | 3439 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3906 | 0.020 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2014 | 644 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 2017 | 1945 | 0.020 |
Why?
|
Body Surface Area | 1 | 2009 | 206 | 0.020 |
Why?
|
Creatinine | 1 | 2014 | 1915 | 0.020 |
Why?
|
Mass Screening | 1 | 2024 | 5451 | 0.020 |
Why?
|
Seizures | 1 | 2021 | 3000 | 0.020 |
Why?
|
Treatment Failure | 1 | 2014 | 2663 | 0.020 |
Why?
|
Blood Glucose | 1 | 2022 | 6430 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7453 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2018 | 3579 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 4039 | 0.020 |
Why?
|
Caregivers | 1 | 2018 | 2303 | 0.020 |
Why?
|
Motor Activity | 1 | 2016 | 2720 | 0.020 |
Why?
|
Poverty | 1 | 2018 | 2721 | 0.020 |
Why?
|
Biological Availability | 1 | 2007 | 392 | 0.020 |
Why?
|
Body Mass Index | 3 | 2009 | 13052 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2014 | 2226 | 0.020 |
Why?
|
Brachial Artery | 1 | 2007 | 373 | 0.020 |
Why?
|
Health Behavior | 1 | 2016 | 2647 | 0.010 |
Why?
|
Self Report | 1 | 2016 | 3766 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2024 | 16028 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2012 | 1391 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 1890 | 0.010 |
Why?
|
Brain | 2 | 2023 | 27454 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2007 | 1502 | 0.010 |
Why?
|
Body Height | 1 | 2009 | 1568 | 0.010 |
Why?
|
Vasodilation | 1 | 2007 | 968 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2014 | 8562 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5512 | 0.010 |
Why?
|
Phenotype | 1 | 2017 | 16721 | 0.010 |
Why?
|
Body Weight | 1 | 2009 | 4629 | 0.010 |
Why?
|
Reference Values | 1 | 2005 | 4941 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6350 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7463 | 0.010 |
Why?
|
Hemodynamics | 1 | 2006 | 4199 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2007 | 4427 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 20765 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12092 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 36849 | 0.010 |
Why?
|
HIV Infections | 1 | 2014 | 17575 | 0.000 |
Why?
|
United States | 1 | 2014 | 73150 | 0.000 |
Why?
|